US FDA Envisions Advisory Committees For Allergy, Asthma Biomarkers With ‘Real Impact’

 
• By Sarah Karlin-Smith
blurred image of people meeting around a oval shaped table
Advisory committees may help FDA decide the utility of biomarkers for allergy and asthma drug development programs • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers